freecandycrushgames| Shenghe Bio-B rose strongly by 11.11% on its first day of listing: a market value of HK$2.35 billion and a net IPO raised HK$390 million

News summary

Newsletter text

May 24freecandycrushgames, Shenghe Bio-B (2898freecandycrushgames.HK) was listed in Hong Kong and performed strongly on the first day of opening, with a maximum increase of 14freecandycrushgames.22%。

The stock hit a high of HK$15.42 in early trading on its first day of listing and closed at HK$15 in afternoon trading, up 11.11% from the IPO issue price of HK$13.5. The turnover on the day reached HK$33.57 million.

Shenghe Bio-B's net IPO fundraising reached HK$390 million, successfully becoming a pioneer in antibody cytokine development company in the Hong Kong capital market.

According to Frost&Sullivan, the company has achieved remarkable results in the field of antibody cytokinesfreecandycrushgamesIt has made significant clinical progress and is one of the global leaders in the field of antibody cytokine products.

Shenghe Bio-B focuses on the field of tumor immunity and autoimmune disease treatment, and has 9 product pipelines under development, 6 of which have entered the clinical stage.

The company is committed to creating innovative First-in-Class products, especially in treating cancer patients. Its pipelines have demonstrated world-leading research and development speed.